What is the typical morphology of lymphocytes in the peripheral blood of an older adult patient diagnosed with Chronic Lymphocytic Leukemia (CLL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Morphology of Lymphocytes in CLL Peripheral Blood

The peripheral blood in CLL shows a predominance of small, morphologically mature lymphocytes, though it is common to find admixtures of larger or atypical cells including prolymphocytes. 1

Core Morphologic Features

The characteristic morphologic appearance includes:

  • Small, mature-appearing lymphocytes that predominate in the blood smear 1
  • Admixtures of larger or atypical cells are commonly present, including cells consistent with prolymphocytes 1
  • Up to 55% prolymphocytes is still consistent with CLL diagnosis (above this threshold suggests prolymphocytic leukemia) 1
  • Occasional lymphoplasmacytic and cleaved cells may be seen, particularly in "atypical CLL" variants 2

Morphologic Variants and Clinical Significance

Approximately 15% of patients show atypical morphology either at diagnosis or during disease progression: 2

  • CLL/PL variant: >10% circulating prolymphocytes 2
  • "Atypical" CLL: >15% lymphoplasmacytic and cleaved cells 2
  • These atypical morphologies correlate with disease progression, advanced stage, trisomy 12, p53 abnormalities, and unmutated immunoglobulin genes 2

Essential Diagnostic Context

While morphology is characteristic, it must be confirmed with immunophenotyping: 1

  • The composite immunophenotype (CD5+, CD19+, CD20+ low, CD23+, surface Ig low, CD79b low, FMC7-) distinguishes CLL from other CD5+ B-cell lymphomas 1
  • Critical pitfall: Mantle cell lymphoma must be excluded, as it can appear morphologically similar but requires different management—absence of cyclin D1 expression or t(11;14) translocation is essential to confirm CLL 1

Diagnostic Threshold

The diagnosis requires ≥5,000 mature-appearing lymphocytes/μL (5 × 10⁹/L) sustained in peripheral blood, combined with the characteristic morphology and immunophenotype. 1, 3

Related Questions

What are the diagnostic criteria and steps for chronic lymphocytic leukemia?
What is the next diagnostic test for a patient with suspected Chronic Lymphocytic Leukemia (CLL)?
What are the diagnostic and treatment approaches for patients presenting with symptoms of Chronic Lymphocytic Leukemia (CLL)?
What are the treatment options for Chronic Lymphocytic Leukemia (CLL)?
What is the appropriate management for a patient presenting with scleral jaundice, a history of Chronic Lymphocytic Leukemia (CLL), and Congestive Heart Failure (CHF)?
What is the appropriate scoring system and treatment for a child or young adult presenting with symptoms of strep throat, such as sore throat, fever, and swollen lymph nodes?
What is the management approach for an adult patient with a history of diabetes presenting with Hyperosmolar Hyperglycemic State (HHS)?
What is the best course of treatment for a female patient with hair thinning, acne, and difficulty losing weight, who has a history of childhood hyperthyroidism and stroke, and is experiencing hirsutism, with normal kidney function, slightly elevated creatinine, normal reproductive hormones, and normal thyroid-stimulating hormone (TSH) levels?
In which Non-ST-Elevation Myocardial Infarction (NSTEMI) patients are Direct Oral Anticoagulants (DOACs) not recommended?
Why are direct oral anticoagulants (DOACs) not recommended for patients with non-ST-elevation myocardial infarction (NSTEMI)?
What is the best management approach for a 23-year-old female patient with pyrosis (heartburn), epigastralgias (epigastric pain), and a history of anxiety?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.